Hollis-Eden Pharmaceuticals Retains Burrill LLC to Provide Exclusive Advisory Services for Lead Programs
October 20 2009 - 9:11AM
PR Newswire (US)
SAN DIEGO, Oct. 20 /PRNewswire-FirstCall/ -- Hollis-Eden
Pharmaceuticals (NASDAQ:HEPH) has retained Burrill LLC to provide
exclusive strategic advisory services, with an initial focus on
partnering Hollis-Eden's lead program Apoptone, currently in Phase
I/II development for hormone-refractory prostate cancer. "We are
very pleased to collaborate with Burrill & Company given their
experience in successfully executing life science transactions,"
said James Frincke, Ph.D. CEO of Hollis-Eden Pharmaceuticals.
Benjamin Chen, Ph.D., Managing Director at Burrill LLC added: "We
look forward to assisting Hollis-Eden now that they have refocused
their business strategy on the advancement of the lead compounds
from their extensive library of synthetic steroid analogs." About
Hollis-Eden Pharmaceuticals Hollis-Eden Pharmaceuticals is a
development-stage company with two candidates in clinical trials:
Apoptone® (HE3235), in the dose-escalation portion of a Phase I/II
trial of patients with late-stage prostate cancer, and Triolex®, in
a Phase IIa trial in obese type 2 diabetes mellitus patients.
Apoptone® and Triolex® represent the lead candidates from
Hollis-Eden's small molecule platform based on metabolites or
synthetic analogs of endogenous steroid hormones. For more
information on Hollis-Eden, please visit http://www.holliseden.com/
About Burrill & Company Founded in 1994, Burrill & Company
is a San Francisco-based global leader in life sciences with
activities in Venture Capital, Private Equity, Merchant Banking and
Media. The Burrill family of venture capital funds has over $1
billion under management and its merchant banking business is one
of the industry leaders in life sciences transactions. Burrill is
also the creator, sponsor and facilitator of over a dozen leading
industry conferences worldwide and publisher of a range of
bio-intelligence reports including the Burrill Report, which tracks
the progress of the global biotechnology industry and annual "State
of the Industry" report. For more information, visit
http://www.burrillandco.com/. This press release contains
forward-looking statements within the meaning of the federal
securities laws concerning, among other things, the potential and
prospects of Hollis-Eden Pharmaceuticals, Inc. regaining and
maintaining compliance with the listing standards of the NASDAQ
Global Market and its drug discovery program and its drug
candidates. Any statement included in this press release that are
not a description of historical facts are forward-looking
statements that involve risks, uncertainties, assumptions and other
factors which, if they do not materialize or prove correct, could
cause Hollis-Eden's actual results to differ materially from
historical results or those expressed or implied by such
forward-looking statements. Such statements are subject to certain
risks and uncertainties inherent in the Company's business,
including, but not limited to: the ability to complete preclinical
and clinical trials successfully and within specified timelines, if
at all; the ability to obtain regulatory approval for TRIOLEX®
(HE3286), APOPTONE® (HE3235) or any other investigational drug
candidate; the Company's future capital needs; the Company's
ability to obtain additional funding; the ability of the Company to
protect its intellectual property rights and to not infringe the
intellectual property rights of others; the development of
competitive products by other companies; and other risks detailed
from time to time in the Company's filings with the Securities and
Exchange Commission. Existing and prospective investors are
cautioned not to place undue reliance on these forward-looking
statements, which speak only as of the date of this press release.
Except as required by law, Hollis-Eden undertakes no obligation to
update or revise the information contained in this press release as
a result of new information, future events or circumstances arising
after the date of this press release. DATASOURCE: Hollis-Eden
Pharmaceuticals CONTACT: Robert Weber, CFO of Hollis-Eden
Pharmaceuticals, +1-858-587-9333, Web Site:
http://www.holliseden.com/
Copyright